Press Release
Pheonix Research Releases 2026–2033 AI in Pharmacy Forecast: 28.89 Per Cent More Sites and 7.81 Per Cent Less Revenue at Each of Them
FOR IMMEDIATE RELEASE
18 November 2026 — Pheonix Research today publishes Global Artificial Intelligence in Pharmacy Market Report, Size, Share and Forecast 2026–2033, which sizes the market at USD 1,840 million in 2025 and forecasts USD 7,310 million by 2033 at an 18.82 per cent compound annual growth rate.
The figure with commercial consequences sits underneath the headline. The number of pharmacy sites running at least one production AI workflow rises from 52,000 to 396,000, a 28.89 per cent CAGR, while revenue per AI-enabled site falls from USD 35,385 to USD 18,460 — 7.81 per cent a year. Every point of value growth in this market is penetration. None of it is price.
“Every point of growth here is a new site, and every site is paying less than the one before it,” said the Pheonix Research healthcare devices team. “That is the opposite of how pharmacy AI is usually presented, and the exact inverse of what the equipment market next door does.”
Key findings
- The mirror image of pharmacy automation. Pheonix Research models pharmacy automation systems at 7.76 per cent a year on 4.90 per cent unit growth and a 2.73 per cent rise in revenue per system. Software runs the other way because a dispensing configuration gets physically larger each generation while a model call gets cheaper.
- Three mechanisms drive the deflation. Inference cost falls year on year; AI rarely arrives as its own line item and is typically quoted as a percentage uplift on an automation bid, which turns it into a discount lever rather than a capability purchase; and the site estate itself is contracting.
- Fewer sites, more throughput each. The National Community Pharmacists Association counted 18,960 independent community pharmacies in July 2025, down from 18,984 a year earlier, with independents at nearly 36 per cent of US retail pharmacy. Average prescription volume per independent store rose from 59,644 in 2023 to 67,601 in 2024, up 13.3 per cent.
- The labour case is better documented than the market size. The ASHP survey of hospital pharmacy directors found 56.2 per cent of hospitals short of pharmacy leadership, with pharmacist involvement in emergency departments up from 10.9 per cent a decade earlier to 46.5 per cent. CMS estimates prior authorisation costs providers USD 20–50 an hour for 13 hours a week — approximately USD 34,000 and 700 hours per provider annually — with certain plans required to operate a Prior Authorization API from 1 January 2027.
- Only 17.77 per cent of the market can be disclosed. Named pools — principally Omnicell, at USD 1,185 million of fiscal 2025 revenue, plus Becton Dickinson’s medication management segment and Cencora’s USD 1 billion distribution investment through 2030 — carry 17.77 per cent of the 2025 base. The remaining 82.23 per cent is a bottom-up estimate, labelled as such.
“AI in pharmacy rarely has its own line in anyone’s accounts,” the team said. “It appears as a feature uplift inside a product or a productivity claim inside a capital programme. Any sizing that claims precision is describing its own assumptions, not the market.”
The forecast states its own weakest assumption
If revenue per site held flat at USD 35,385 while the site count still reached 396,000, the 2033 market would be approximately USD 14,012 million — nearly double the base case. The forecast is therefore a statement about price, not about adoption, and the report says so on the page rather than in a footnote.
Report details
- Title: Global Artificial Intelligence in Pharmacy Market Report, Size, Share and Forecast 2026–2033: Twenty-Nine Per Cent More Sites and Eight Per Cent Less Revenue Per Site
- Base year and horizon: 2025 base, forecast to 2033.
- Coverage: global, by workflow — dispensing and verification, medication adherence, inventory and supply, prior authorisation and benefit investigation, and clinical decision support — across retail, hospital, central-fill and long-term care settings.
- Chapters: market sizing and forecast; value chain and cost structure; technology and innovation; competitive landscape; investment activity; market risk and scenarios; regulatory landscape.
- Methodology: a 70/30 split of secondary and primary research, with primary work concentrated on price bands, the specification chain, switching costs and the payback arithmetic buyers apply. No market-research competitor data is used as an input.
- Available at: pheonixresearch.com/healthcare/medical-devices/market-report/artificial-intelligence-ai-pharmacy-market/
About Pheonix Research
Pheonix Research is a market intelligence platform that queries a live graph of more than 500 market nodes to surface leading signals and translate them into role-specific decisions. It publishes market reports across industrial, healthcare and technology sectors, built from disclosed primary sources, a structured primary research programme, and a documented model in which every estimated figure is identified as an estimate.
Media contact
Pheonix Research
Research & Intelligence: [email protected]
Sales & Engagements: [email protected]
Website: www.pheonixresearch.com
— Ends —
